• العربية
    • English
  • English 
    • العربية
    • English
  • Login
Home
Publisher PoliciesTerms of InterestHelp Videos
Submit Thesis
IntroductionIUGSpace Policies
JavaScript is disabled for your browser. Some features of this site may not work without it.
View Item 
  •   Home
  • Faculty of Science
  • PhD and MSc Theses- Faculty of Science
  • View Item
  •   Home
  • Faculty of Science
  • PhD and MSc Theses- Faculty of Science
  • View Item

Please use this identifier to cite or link to this item:

http://hdl.handle.net/20.500.12358/21796
TitleCYP2C19 Polymorphism in Childhood Hematological Malignancy
Untitled
Abstract

Cytochrome P450 2C19 (CYP2C19) participates in the metabolism of many clinically important drugs and many xenobiotic compounds. Genetic polymorphisms of the CYP2C19 gene are described to have possible effect on drug treatment and increasing susceptibility to carcinogenic substances. The aim of this study was to determine the frequencies of the major polymorphic CYP2C19 alleles (CYP2C19*2 and CYP2C19*3) and to investigate their association with occurrence of childhood hematological malignancies and/or age of onset of the disease in the investigated patients with comparison to normal subjects. The polymorphism of CYP2C19 was analyzed by a genotyping technique, based on polymerase chain reaction (PCR) followed by restriction enzyme analysis. EDTA blood samples were obtained from 52 previously diagnosed hematological malignancy children (45 from El-Nasser hospital and 7 from the European Gaza hospital) and from 52 normal subjects. The DNA was extracted from the EDTA blood sample for each child. The frequencies of each allele in the cancer group and the control group were compared. In the patient group the frequencies of CYP2C19*2 and CYP2C19*3 were 9.62% and 0.96%, respectively, while in the control group the respective frequencies were 5.77% and 2.88%. These percentages show that there is no significant difference between the control group and the patient group in terms of the frequencies of CYP2C19*2 and CYP2C19*3. The genotyping analysis showed the following results: 15.39% (1*/2*), 1.92% (1*/3*), 1.92% (2*/2*), and 80.77% (1*/1*) in the patients while in the normal subjects the results were 7.69% (1*/2*) , 5.77% (1*/3*), 1.92% (2*/2*), and 84.61% (1*/1*). Data also showed that there is no significant Correlation between the onset age and the polymorphism of the CYP2C19. Moreover, the frequency of affected males was more than that of females. In conclusion, no significant association was found between the CYP2C19 polymorphism and the occurrence or the onset age of the childhood hematological malignancies. Further studies are needed to investigate more CYP2C19 alleles and other important CYP genes polymorphisms in cancer patients.

Authors
Abu_eid, Sameer Ibrahim
Supervisors
A.abed, Abdalla
A.sharif, Fadel
Typeرسالة ماجستير
Date2006
LanguageEnglish
Publisherthe islamic university
Citation
License
Collections
  • PhD and MSc Theses- Faculty of Science [445]
Files in this item
file_1.pdf646.3Kb
Thumbnail

The institutional repository of the Islamic University of Gaza was established as part of the ROMOR project that has been co-funded with support from the European Commission under the ERASMUS + European programme. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

Contact Us | Send Feedback
 

 

Browse

All of IUGSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsSupervisorsThis CollectionBy Issue DateAuthorsTitlesSubjectsSupervisors

My Account

LoginRegister

Statistics

View Usage Statistics

The institutional repository of the Islamic University of Gaza was established as part of the ROMOR project that has been co-funded with support from the European Commission under the ERASMUS + European programme. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

Contact Us | Send Feedback